Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial

Edward R Scheffer Cliff¹, Thomas E Lew¹, Florian Simon¹+4

• ¹Edward R. Scheffer Cliff, MPH, MBBS, Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia; Thomas E. Lew, MBBS, Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia, Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia; Florian Simon, MD, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Talal Hilal, MD, Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ; and Mary Ann Anderson, PhD, MBBS; Philip A. Thompson, MBBS; and John F. Seymour, PhD, MBBS, Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia, Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.